Key Events This Week
15 Sep: Technical momentum shifts amid mixed indicator signals
16 Sep: Downgrade to Hold by MarketsMOJO reflecting cautious outlook
18 Sep: Week closes at Rs.606.40, down 2.98%
Sep 23, 02:01 PM
BSE+NSE Vol: 13.19 k
15 Sep: Technical momentum shifts amid mixed indicator signals
16 Sep: Downgrade to Hold by MarketsMOJO reflecting cautious outlook
18 Sep: Week closes at Rs.606.40, down 2.98%

Lincoln Pharmaceuticals Ltd has seen its investment rating downgraded from Buy to Hold as of 15 Sep 2026, reflecting a nuanced reassessment across quality, valuation, financial trends, and technical indicators. Despite solid financial performance and market-beating returns over the medium term, evolving technical signals and cautious valuation metrics have prompted a more measured stance on the stock.
Read full news article
Lincoln Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from bullish to mildly bullish territory. Despite a recent dip in price, the stock’s longer-term technicals and fundamental backdrop continue to offer a cautiously optimistic outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
7 Sep: Stock opens at Rs.633.00, up 2.30% despite Sensex decline
8 Sep: Technical and fundamental upgrade to Buy rating announced
9 Sep: Stock hits intraday high of Rs.647.00, closes at Rs.640.55 (+1.19%)
11 Sep: Week closes at Rs.625.05, down 1.78% on the day but positive for the week

Lincoln Pharmaceuticals Ltd has been upgraded from a Hold to a Buy rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical outlook. The upgrade reflects the company’s robust quarterly financial results, improved technical indicators, and attractive valuation metrics relative to its peers, signalling renewed investor confidence in this micro-cap pharmaceutical stock.
Read full news article
Lincoln Pharmaceuticals Ltd has demonstrated a notable shift in price momentum, supported by a series of technical indicator upgrades that signal a strengthening bullish trend. With a recent upgrade in its Mojo Grade from Hold to Buy and a current market price of ₹640.55, the micro-cap pharmaceutical company is attracting renewed investor interest amid mixed but improving technical signals.
Read full news article
Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 August 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleLincoln Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal a complex picture characterized by strong revenue growth but stagnant profitability. The company reported net sales of ₹187.28 crores, reflecting an 11.36% increase year-on-year, driven by robust domestic demand and export performance. However, net profit showed only a marginal growth of 0.43% year-on-year, amounting to ₹11.63 crores, which raises concerns about operational efficiency as profitability did not keep pace with revenue expansion. The operating margin for Q4 FY26 was recorded at 13.27%, a decline of 262 basis points compared to the previous year, indicating pressures from rising input costs and increased employee expenses. This margin compression highlights challenges in maintaining profitability amid a competitive landscape. The profit after tax margin also contracted to 6.21%, down from 6.89% in the previous year, furth...
Read full news articleNewspaper Publication for Notice of 32nd Annual General Meeting.
Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.
Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ("the SEBI Listing Regulations") we are submitting herewith the Annual Report of the Company along with the Notice of 32nd Annual General Meeting ("AGM") for the Financial Year 2025-2026.
No Upcoming Board Meetings
Lincoln Pharmaceuticals Ltd has declared 18% dividend, ex-date: 11 Sep 26
Lincoln Pharmaceuticals Ltd has announced 10:2 stock split, ex-date: 19 Mar 09
No Bonus history available
No Rights history available